{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:54:56Z","timestamp":1793656496067,"version":"4.5.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1053\/j.ajkd.2022.04.016","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T23:33:38Z","timestamp":1661988818000},"page":"658-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms"],"prefix":"10.1053","volume":"80","author":[{"given":"Murray","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Clase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2022.04.016_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2022.04.016_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.604928","article-title":"The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria and has improved therapeutic index compared with eplerenone in a rat model with mineralocorticoid-induced renal injury","volume":"12","author":"Jaisser","year":"2021","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1053\/j.ajkd.2022.04.016_bib3","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"23","key":"10.1053\/j.ajkd.2022.04.016_bib4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2022.04.016_bib5","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2022.04.016_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1681\/ASN.2019080804","article-title":"Two mineralocorticoid receptor-mediated mechanisms of pendrin activation in distal nephrons","volume":"31","author":"Ayuzawa","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2022.04.016_bib8","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.016_bib9","doi-asserted-by":"crossref","first-page":"T23","DOI":"10.1530\/JOE-17-0060","article-title":"30 Years of the mineralocorticoid receptor: coregulators as mediators of mineralocorticoid receptor signalling diversity","volume":"234","author":"Fuller","year":"2017","journal-title":"J\u00a0Endocrinol"},{"issue":"11","key":"10.1053\/j.ajkd.2022.04.016_bib10","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1210\/en.2010-0465","article-title":"Minireview: aldosterone and mineralocorticoid receptors: past, present, and future","volume":"151","author":"Funder","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1053\/j.ajkd.2022.04.016_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/HYPERTENSIONAHA.120.16397","article-title":"Effect of mineralocorticoid receptor blockade on arterial stiffness and endothelial function: a meta-analysis of randomized trials","volume":"77","author":"Sakima","year":"2021","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ajkd.2022.04.016_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1053\/j.ajkd.2022.04.016_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1152\/physrev.1992.72.3.563","article-title":"Renal effects of head-out water immersion in humans: a 15-year update","volume":"72","author":"Epstein","year":"1992","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1053\/j.ajkd.2022.04.016_bib14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"issue":"2","key":"10.1053\/j.ajkd.2022.04.016_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"issue":"22","key":"10.1053\/j.ajkd.2022.04.016_bib16","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2022.04.016_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1053\/j.ajkd.2022.04.016_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ndt\/gfab254","article-title":"The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury","volume":"37","author":"Epstein","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2022.04.016_bib19","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","article-title":"Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts","volume":"33","author":"Leifheit-Nestler","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2022.04.016_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.649921","article-title":"Aldosterone is positively associated with circulating FGF23 levels in chronic kidney disease across four species, and may drive FGF23 secretion directly","volume":"12","author":"Radloff","year":"2021","journal-title":"Front Physiol"},{"issue":"12","key":"10.1053\/j.ajkd.2022.04.016_bib21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/ndt\/gfy315","article-title":"Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease","volume":"34","author":"Xu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2022.04.016_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bone.2017.01.017","article-title":"Potential application of klotho in human chronic kidney disease","volume":"100","author":"Neyra","year":"2017","journal-title":"Bone"},{"issue":"9","key":"10.1053\/j.ajkd.2022.04.016_bib23","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11255-016-1319-7","article-title":"Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis","volume":"48","author":"Lu","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2022.04.016_bib24","first-page":"88","article-title":"Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride","volume":"49","author":"Selye","year":"1943","journal-title":"Can Med Assoc J"},{"issue":"11","key":"10.1053\/j.ajkd.2022.04.016_bib25","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2022.04.016_bib26","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1053\/j.ajkd.2022.04.016_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2022.04.016_bib28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","article-title":"Aldosterone antagonism in chronic kidney disease","volume":"1","author":"Ponda","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1 Pt 2","key":"10.1053\/j.ajkd.2022.04.016_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ajkd.2022.04.016_bib30","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2022.04.016_bib31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2022.04.016_bib32","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2022.04.016_bib33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1053\/j.ajkd.2022.04.016_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-020-1023-y","article-title":"Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists","volume":"22","author":"Sueta","year":"2020","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2022.04.016_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259485","article-title":"Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: a retrospective study","volume":"16","author":"Iwahana","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1053\/j.ajkd.2022.04.016_bib36","first-page":"143","article-title":"Preclinical development of KBP-5074, a novel non-steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases","volume":"4","author":"Chow","year":"2018","journal-title":"J\u00a0Drug Res Dev"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.016_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on\u00a0blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD Study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ajkd.2022.04.016_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1053\/j.ajkd.2022.04.016_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.006260","article-title":"Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study","volume":"13","author":"Zareini","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"10.1053\/j.ajkd.2022.04.016_bib40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"Suppl 1","key":"10.1053\/j.ajkd.2022.04.016_bib41","first-page":"S175","article-title":"11. Chronic kidney disease and risk management: standards of medical care in diabetes 2022","volume":"45","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1053\/j.ajkd.2022.04.016_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2022.04.016_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2022.04.016_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2215\/CJN.13541021","article-title":"Hyperkalemia with mineralocorticoid receptor antagonist use in people with CKD: understanding and mitigating the risks","volume":"17","author":"Epstein","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2022.04.016_bib45","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2215\/CJN.02150221","article-title":"The rales legacy and finerenone use on CKD patients","volume":"16","author":"Moura-Neto","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2022.04.016_bib46","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"31","key":"10.1053\/j.ajkd.2022.04.016_bib47","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.016_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.016_bib49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"issue":"48","key":"10.1053\/j.ajkd.2022.04.016_bib50","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622007442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622007442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:46:22Z","timestamp":1759463182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622007442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0272638622007442"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.04.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}